Remarkable response of primary squamous cell carcinoma of the ovary to paclitaxel and cisplatin.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 9572185.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The survival rate of patients with advanced stage primary squamous cell carcinoma of the ovary is dismal and the best treatment is unknown. We describe the response of this tumor to systemic chemotherapy employing paclitaxel and cisplatin. A 31-year-old white woman diagnosed with International Federation of Gynecology and Obstetrics stage IV primary squamous cell carcinoma of the ovary associated with ovarian endometriosis underwent cytoreductive surgery followed by paclitaxel and cisplatin every 4 weeks for 12 courses. The patient tolerated chemotherapy well, demonstrated a dramatic response with disappearance of hepatic metastases, and remains without evidence of disease 2 years after diagnosis. Paclitaxel and cisplatin may be effective in treating primary squamous cell carcinoma of the ovary.
Medical subject headings
- Adult
- Antineoplastic Combined Chemotherapy Protocols
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Carcinoma, Squamous Cell
- Carcinoma, Squamous Cell/diagnostic imaging
- Carcinoma, Squamous Cell/drug therapy
- Carcinoma, Squamous Cell/secondary
- Cisplatin
- Cisplatin/administration & dosage
- Combined Modality Therapy
- Female
- Humans
- Liver Neoplasms
- Liver Neoplasms/secondary
- Ovarian Neoplasms
- Ovarian Neoplasms/diagnostic imaging
- Ovarian Neoplasms/drug therapy
- Ovarian Neoplasms/pathology
- Paclitaxel
- Paclitaxel/administration & dosage
- Tomography, X-Ray Computed